#USA #Baltimore #ALS #DarwinCell #ALT001

DarwinCell Unveils ALT001 at ANA 2025

The 150th American Neurological Association Annual Meeting, held in Baltimore, Maryland from September 13 to 16, 2025, served as a pivotal platform for the latest advancements in neuroscience. Among the standout presentations was DarwinCell's unveiling of ALT001, a novel drug aimed at treating Amyotrophic Lateral Sclerosis (ALS).

Background of ALS

ALS, a progressive neurodegenerative disease, primarily leads to the degeneration of motor neurons, resulting in muscle weakness and atrophy, which can be fatal due to respiratory complications. The disease can onset at a startlingly young age, with some patients developing symptoms in their twenties. In China, ALS affects approximately 0.6 individuals per 100,000, with a disappointing typical survival period of 3-5 years. Current primary treatments remain limited to Riluzole and Edaravone, highlighting an urgent need for innovative therapies.

Breakthrough Data on ALT001

DarwinCell's poster presentation on ALT001 captured significant interest at the conference, earning the prestigious "Abstract of Distinction." The drug is based on mesenchymal stem cell (MSC) technology and demonstrated considerable promise in preclinical studies. Initial investigations, including in vitro experiments and Initial Investigator Trials (IIT) involving over 40 ALS patients, revealed that ALT001 not only protected motoneurons from neurotoxicity but also mitigated muscle atrophy in transgenic mouse models. These mice showed marked improvement in motor functions and an extended lifespan when treated with ALT001 compared to controls.

The clinical trial findings were equally encouraging, with most participants reporting enhanced clinical outcomes after two weeks of ALT001 treatment. This was measured using metrics like the Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) and the modified Norris score.

Commitment to Innovation

Ms. Wang Yu, Founder and CEO of DarwinCell, expressed her enthusiasm for presenting ALT001's findings at such a significant global conference. She emphasized the company's dedication to advancing this therapy further, not just for ALS but for a range of neurological conditions.

"ALT001 represents a blend of cell therapy functionality with the practicality of traditional biologics, optimizing effectiveness, safety, and accessibility for patients," Ms. Wang stated. This indicates DarwinCell's resolve to deepen its involvement in the fields of neuroscience and regenerative medicine. The company plans to expedite IND applications for ALT001 both in China and the U.S., aiming to bring a renewed sense of hope to those affected by neurodegenerative diseases worldwide.

About DarwinCell

Founded in 2016, DarwinCell has rapidly established itself as a leader in neurological disease treatment innovation. Utilizing proprietary protein polymer extraction technology, they have developed a comprehensive platform spanning drug discovery to clinical application. Collaborating with leading medical institutions, DarwinCell is on track to become an internationally recognized innovator in neural repair technology.

For potential updates and further information about DarwinCell and its innovative therapies, visit DarwinCell's website.